Lupin expects India sales to grow 18-20 pct in fiscal 2015; net profit jumps

MUMBAI Wed Jul 30, 2014 3:21pm IST

An employee of Lupin Limited works at a reception at their headquarters in Mumbai November 22, 2013. REUTERS/Danish Siddiqui/Files

An employee of Lupin Limited works at a reception at their headquarters in Mumbai November 22, 2013.

Credit: Reuters/Danish Siddiqui/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - Drugmaker Lupin Ltd (LUPN.NS) expects its local business to grow between 18 and 20 percent this fiscal year, its chief executive said, after higher sales in the domestic market helped it post a 56 percent jump in quarterly net profit.

India, which made up nearly a fourth of Lupin's total sales in the June quarter, was a drag on its earnings in January-March as many of the company's drugs fell under the federal government's price cap order of last year.

India sales grew 29 percent in the quarter ended June, its fiscal first quarter, the company said on Wednesday.

Lupin, India's fourth-largest generic drugmaker by sales, has been on the lookout for acquisitions that would enhance its branded generics business in the United States, its biggest market.

Lupin is one of several firms planning to bid for a portfolio of older drugs being auctioned by Britain's GlaxoSmithKline Plc (GSK.L), sources familiar with the matter told Reuters last week.

"We are continuously on the lookout for opportunities that enhance our technology capabilities," Chief Executive Vinita Gupta said. She declined to comment on the GlaxoSmithKline auction.

PROFIT BEATS ESTIMATES

Lupin reported a first-quarter net profit of 6.25 billion rupees ($103.92 million), compared with 4.01 billion rupees a year earlier. Analysts on average expected a profit of 5.10 billion rupees, according to Thomson Reuters data.

Net sales rose 36 percent to 32.84 billion rupees, helped largely by a 57 percent jump in its formulation business in the United States, which accounted for 49 percent of its sales in the June quarter.

Rival Dr Reddy's Laboratories Ltd (REDY.NS), India's No.2 drugmaker by sales, on Wednesday reported a 52 percent jump in net profit to 5.5 billion rupees, in line with estimates, as its North American sales rose 51 percent in the June quarter.

Lupin's shares were up 4.5 percent at 1,169.35 rupees at 0935 GMT, while those of Dr Reddy's were up 1.7 percent at 2,817.20 rupees. The Nifty was up 0.5 percent.

($1 = 60.14 rupees)

(Editing by Sumeet Chatterjee and Matt Driskill)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Fuelling Change

REUTERS SHOWCASE

NSEL Fraud

NSEL Fraud

Govt orders Financial Tech to absorb NSEL, liabilities  Full Article 

Stalemate

Stalemate

WTO prepares for crisis talks as India keeps veto on global deal.  Full Article 

Deal Talk

Deal Talk

Smartphone repair company B2X steps up expansion with Indian deal.  Full Article 

Earnings Season

Earnings Season

HDFC Bank eyes pickup in corporate credit.  Full Article 

JLR China

JLR China

JLR sees 20 percent growth in China sales this year - exec  Full Article 

Iron Ore Imports

Iron Ore Imports

JSW Steel to boost iron ore imports by up to 80 percent.  Full Article 

Pollution Levels

Pollution Levels

Delhi braces for worst air quality this Diwali week.  Full Article 

Remembering Margerie

Remembering Margerie

Total’s "Big Moustache"- bon vivant, deal-maker and risk-taker .  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage